Your browser is no longer supported. Please, upgrade your browser.
LNTH Lantheus Holdings, Inc. monthly Stock Chart
Lantheus Holdings, Inc.
Index- P/E44.01 EPS (ttm)0.30 Insider Own1.90% Shs Outstand39.43M Perf Week-1.41%
Market Cap964.59M Forward P/E14.11 EPS next Y0.94 Insider Trans-8.59% Shs Float- Perf Month-7.45%
Income11.60M PEG2.46 EPS next Q0.03 Inst Own66.60% Short Float- Perf Quarter3.02%
Sales331.80M P/S2.91 EPS this Y-23.00% Inst Trans4.37% Short Ratio3.13 Perf Half Y-22.01%
Book/sh3.00 P/B4.43 EPS next Y88.40% ROA7.90% Target Price21.25 Perf Year-43.45%
Cash/sh1.32 P/C10.08 EPS next 5Y17.90% ROE29.70% 52W Range8.67 - 27.12 Perf YTD-35.20%
Dividend- P/FCF16.55 EPS past 5Y51.00% ROI16.70% 52W High-51.00% Beta1.20
Dividend %- Quick Ratio2.40 Sales past 5Y2.90% Gross Margin45.20% 52W Low53.29% ATR0.71
Employees508 Current Ratio2.90 Sales Q/Q4.90% Oper. Margin14.60% RSI (14)40.04 Volatility5.56% 4.89%
OptionableYes Debt/Eq1.62 EPS Q/Q-66.70% Profit Margin9.50% Rel Volume0.85 Prev Close13.03
ShortableYes LT Debt/Eq1.53 EarningsJul 30 BMO Payout0.00% Avg Volume728.44K Price13.29
Recom2.00 SMA20-10.34% SMA50-7.74% SMA200-17.25% Volume618,450 Change2.00%
Jun-29-20Resumed Jefferies Buy $29
Aug-16-19Upgrade CJS Securities Market Perform → Market Outperform
Nov-02-17Upgrade Wells Fargo Market Perform → Outperform
Nov-08-16Reiterated RBC Capital Mkts Outperform $6 → $12
Sep-23-16Resumed Credit Suisse Neutral
Feb-24-16Reiterated RBC Capital Mkts Outperform $9 → $6
Dec-11-15Downgrade Credit Suisse Outperform → Neutral
Sep-30-15Downgrade Wells Fargo Outperform → Market Perform
Jul-20-15Initiated Wells Fargo Outperform
Jul-20-15Initiated Robert W. Baird Outperform $10
Jul-20-15Initiated RBC Capital Mkts Outperform $10
Jul-20-15Initiated Jefferies Buy $12
Jul-20-15Initiated Credit Suisse Outperform $10
Jul-30-20 12:00PM  
Jul-29-20 03:06PM  
Jul-28-20 10:25AM  
Jul-23-20 08:00AM  
Jul-01-20 08:00AM  
Jun-22-20 12:11PM  
Jun-17-20 05:33PM  
Jun-16-20 04:05PM  
May-27-20 07:53PM  
May-20-20 04:30PM  
May-05-20 04:30PM  
May-01-20 07:31PM  
Apr-30-20 06:30PM  
Apr-16-20 08:30AM  
Apr-14-20 11:17AM  
Apr-09-20 08:30AM  
Apr-06-20 08:30AM  
Apr-04-20 10:15AM  
Apr-02-20 02:58PM  
Mar-17-20 07:58AM  
Feb-28-20 07:06AM  
Feb-27-20 02:10PM  
Feb-26-20 09:36AM  
Feb-25-20 07:00AM  
Feb-24-20 02:18PM  
Feb-21-20 07:46AM  
Feb-20-20 11:30AM  
Feb-18-20 09:00AM  
Feb-03-20 08:30AM  
Jan-28-20 09:27AM  
Jan-27-20 08:30AM  
Jan-13-20 08:30AM  
Jan-02-20 02:24PM  
Dec-13-19 12:53PM  
Dec-09-19 12:57PM  
Nov-21-19 04:05PM  
Nov-12-19 12:29PM  
Nov-07-19 08:12AM  
Nov-01-19 01:14AM  
Oct-31-19 08:55AM  
Oct-29-19 04:30PM  
Oct-28-19 02:00PM  
Oct-27-19 06:39PM  
Oct-24-19 10:32AM  
Oct-23-19 09:55AM  
Oct-17-19 04:05PM  
Oct-16-19 10:16AM  
Oct-11-19 03:20PM  
Oct-08-19 04:11PM  
Oct-04-19 06:14PM  
Oct-03-19 10:52AM  
Oct-02-19 03:12PM  
Sep-26-19 02:14PM  
Sep-06-19 07:48AM  
Sep-05-19 07:15PM  
Aug-22-19 04:05PM  
Aug-17-19 07:56AM  
Jul-31-19 01:39AM  
Jul-29-19 07:02PM  
Jul-28-19 10:04AM  
Jul-25-19 08:55AM  
Jul-18-19 10:33AM  
Jul-13-19 07:28AM  
Jul-11-19 04:05PM  
Jul-08-19 12:07PM  
Jun-24-19 09:00AM  
Jun-20-19 04:15PM  
Jun-19-19 06:38PM  
Jun-11-19 11:46AM  
May-30-19 05:00PM  
May-22-19 04:05PM  
May-08-19 02:27PM  
May-07-19 04:05PM  
May-01-19 11:08PM  
Apr-30-19 01:49PM  
Apr-19-19 09:30AM  
Apr-16-19 04:05PM  
Apr-15-19 12:37PM  
Apr-04-19 06:00AM  
Apr-03-19 04:39PM  
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment follow-up of neuroendocrine tumors. It sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has a strategic collaboration and license agreement with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting research and development on PD-L1 immuno-oncology treatments. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Heino Mary AnnePresident & CEOJul 23Sale16.023,00048,051604,793Jul 27 04:30 PM
Heino Mary AnnePresident & CEOJul 15Sale16.0122,125354,254607,793Jul 17 04:30 PM
Bolla John J.Chief Operations OfficerJun 16Sale14.292,42234,60360,419Jun 18 04:30 PM
DUFFY MICHAEL PSVP and General CounselApr 28Sale13.137,19894,529133,402Apr 30 06:35 PM
Heino Mary AnnePresident & CEOApr 27Sale13.7730,033413,407634,318Apr 29 04:30 PM
DUFFY MICHAEL PSVP and General CounselMar 06Sale14.581,93628,229140,600Mar 10 04:30 PM
Heino Mary AnnePresident & CEOMar 05Sale15.359,019138,408664,351Mar 05 04:31 PM
Marshall Robert J. Jr.CFO and TreasurerFeb 28Sale15.4588913,73150,993Mar 02 04:34 PM
Heino Mary AnnePresident & CEOFeb 27Sale16.0525,000401,288524,399Feb 28 04:32 PM
Marshall Robert J. Jr.CFO and TreasurerFeb 27Sale15.791,54624,40751,882Mar 02 04:34 PM
Bolla John J.Chief Operations OfficerFeb 27Sale15.791,25119,75035,154Mar 02 04:33 PM
McHugh JulieDirectorFeb 27Sale15.861,75627,84515,754Mar 02 04:34 PM
LENO SAM RDirectorFeb 27Sale15.852,70042,79235,372Mar 02 04:32 PM
DUFFY MICHAEL PSVP and General CounselFeb 27Sale15.791,55224,501116,493Mar 02 04:30 PM
Robertson A FrederickDirectorFeb 27Sale15.862,66042,19340,402Mar 02 04:30 PM
Heino Mary AnnePresident & CEOFeb 26Sale17.096,615113,031549,399Feb 28 04:32 PM
Heino Mary AnnePresident & CEOFeb 24Sale16.069,898158,970556,014Feb 26 04:30 PM
Heino Mary AnnePresident & CEODec 20Sale20.8519,260401,602563,034Dec 23 04:30 PM
Marshall Robert J. Jr.CFO and TreasurerDec 16Sale20.826,351132,22853,428Dec 18 04:31 PM
LENO SAM RDirectorDec 13Sale20.3011,508233,55538,072Dec 17 04:31 PM
DUFFY MICHAEL PSVP and General CounselNov 14Sale20.797,500155,925123,890Nov 18 04:30 PM
Marshall Robert J. Jr.CFO and TreasurerOct 16Sale19.074,80991,69859,779Oct 18 04:30 PM
Heino Mary AnnePresident & CEOSep 20Sale25.8115,590402,448582,294Sep 24 04:30 PM
DUFFY MICHAEL PSVP and General CounselSep 12Sale23.747,500178,028131,390Sep 16 04:30 PM
DUFFY MICHAEL PSVP and General CounselSep 04Sale20.605,604115,465138,890Sep 06 04:30 PM
Heino Mary AnnePresident & CEOSep 03Sale21.2125,538541,679597,884Sep 05 04:30 PM